PMID- 19650867
OWN - NLM
STAT- MEDLINE
DCOM- 20100629
LR  - 20211020
IS  - 1600-0625 (Electronic)
IS  - 0906-6705 (Print)
IS  - 0906-6705 (Linking)
VI  - 19
IP  - 3
DP  - 2010 Mar
TI  - Anti-IL5 decreases the number of eosinophils but not the severity of dermatitis 
      in Sharpin-deficient mice.
PG  - 252-8
LID - 10.1111/j.1600-0625.2009.00944.x [doi]
AB  - Sharpin-deficient (Sharpin(cpdm)) mutant mice develop a chronic eosinophilic 
      dermatitis. To determine the efficacy of eosinophil-depletion in chronic 
      inflammation, Sharpin(cpdm) mice were treated with anti-IL5 antibodies. Mice 
      treated with anti-IL5 had a 90% reduction of circulating eosinophils and a 50% 
      decrease in cutaneous eosinophils after 10 days compared with sham-treated 
      littermates. Reducing the number of eosinophils resulted in increased severity of 
      alopecia and erythema and a significant increase in epidermal thickness. Skin 
      homogenates from mice treated with anti-IL5 had decreased mRNA expression of 
      arylsulfatase B (Arsb), diamine oxidase (amiloride-binding protein 1, also called 
      histaminase; Abp1) and Il10, which are mediators that eosinophils may release to 
      quench inflammation. Skin homogenates from mice treated with anti-IL5 also had 
      decreased mRNA expression of Il4, Il5, Ccl11, kit ligand (Kitl) and Tgfa; and 
      increased mRNA expression of Tgfb1, Mmp12 and tenascin C (Tnc). In order to 
      further decrease the accumulation of eosinophils, Sharpin(cpdm) mice were crossed 
      with IL5 null mice. Il5(-/-), Sharpin(cpdm)/Sharpin(cpdm) mice had a 98% 
      reduction of circulating eosinophils and a 95% decrease in cutaneous eosinophils 
      compared with IL5-sufficient Sharpin(cpdm) mice. The severity of the lesions was 
      similar between IL5-sufficient and IL5-deficient mice. Double mutant mice had a 
      significant decrease in Abp1, and a significant increase in Tgfb1, Mmp12 and Tnc 
      mRNA compared with controls. These data indicate that eosinophils are not 
      essential for the development of dermatitis in Sharpin(cpdm) mice and suggest 
      that eosinophils have both pro-inflammatory and anti-inflammatory roles in the 
      skin of these mice.
FAU - Renninger, Matthew L
AU  - Renninger ML
AD  - Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, 
      USA.
FAU - Seymour, Rosemarie E
AU  - Seymour RE
FAU - Whiteley, Laurence O
AU  - Whiteley LO
FAU - Sundberg, John P
AU  - Sundberg JP
FAU - Hogenesch, Harm
AU  - Hogenesch H
LA  - eng
GR  - K08 AI060707-01A1/AI/NIAID NIH HHS/United States
GR  - R01 AR049288/AR/NIAMS NIH HHS/United States
GR  - R01 AR049288-01A2/AR/NIAMS NIH HHS/United States
GR  - AR49288-01/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20090723
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-5)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (sharpin)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Neutralizing/therapeutic use
MH  - Cytokines/genetics
MH  - Dermatitis/blood/*immunology/pathology/*therapy
MH  - Eosinophilia/blood/*immunology/pathology/*therapy
MH  - Eosinophils/*immunology/pathology
MH  - Female
MH  - Inflammation Mediators/metabolism
MH  - Interleukin-5/*antagonists & inhibitors/deficiency/genetics/immunology
MH  - Leukocyte Count
MH  - Matrix Metalloproteinases/genetics
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Nerve Tissue Proteins/*deficiency/genetics/immunology
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats
PMC - PMC2852468
MID - NIHMS168006
EDAT- 2009/08/05 09:00
MHDA- 2010/06/30 06:00
PMCR- 2011/03/01
CRDT- 2009/08/05 09:00
PHST- 2009/08/05 09:00 [entrez]
PHST- 2009/08/05 09:00 [pubmed]
PHST- 2010/06/30 06:00 [medline]
PHST- 2011/03/01 00:00 [pmc-release]
AID - EXD944 [pii]
AID - 10.1111/j.1600-0625.2009.00944.x [doi]
PST - ppublish
SO  - Exp Dermatol. 2010 Mar;19(3):252-8. doi: 10.1111/j.1600-0625.2009.00944.x. Epub 
      2009 Jul 23.